Evidence map›Paper›PMID 34499764›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2021

Low lysophosphatidylcholine induces skeletal muscle myopathy that is aggravated by high-fat diet feeding.

Patrick J Ferrara, Anthony R P Verkerke, J Alan Maschek, Justin L Shahtout, Piyarat Siripoksup, Hiroaki Eshima, Jordan M Johnson, Jonathan J Petrocelli, Ziad S Mahmassani, Thomas D Green and 4 more

Open access · greenAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Muscle-specific Keap1 deletion enhances force production but does not prevent inactivity-induced muscle atrophy in mice.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Patrick J FerraraDiabetes and Metabolism Research Center, University of Utah, Salt Lake City, Utah, USA.
Anthony R P VerkerkeDiabetes and Metabolism Research Center, University of Utah, Salt Lake City, Utah, USA.
J Alan MaschekDiabetes and Metabolism Research Center, University of Utah, Salt Lake City, Utah, USA.
Justin L ShahtoutDiabetes and Metabolism Research Center, University of Utah, Salt Lake City, Utah, USA.
Piyarat SiripoksupDiabetes and Metabolism Research Center, University of Utah, Salt Lake City, Utah, USA.
Hiroaki EshimaDiabetes and Metabolism Research Center, University of Utah, Salt Lake City, Utah, USA.
Jordan M JohnsonDiabetes and Metabolism Research Center, University of Utah, Salt Lake City, Utah, USA.
Jonathan J PetrocelliDiabetes and Metabolism Research Center, University of Utah, Salt Lake City, Utah, USA.
Ziad S MahmassaniDiabetes and Metabolism Research Center, University of Utah, Salt Lake City, Utah, USA.
Thomas D GreenEast Carolina Diabetes & Obesity Institute, East Carolina University, Greenville, North Carolina, USA.
Joseph M McClungEast Carolina Diabetes & Obesity Institute, East Carolina University, Greenville, North Carolina, USA.
James E CoxDiabetes and Metabolism Research Center, University of Utah, Salt Lake City, Utah, USA.
Micah J DrummondDiabetes and Metabolism Research Center, University of Utah, Salt Lake City, Utah, USA.ORCID 0000-0001-5961-8890
Katsuhiko FunaiDiabetes and Metabolism Research Center, University of Utah, Salt Lake City, Utah, USA.ORCID 0000-0003-3802-4756
University of Utah · USEast Carolina University · USNagasaki International University · JP

Funding

WU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI Clay F. Semenkovich · 2013 to 2026
$27.1M
Proteomics CoreU54DK110858 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Anna E Beaudin, JAMES Eric COX · 2016 to 2026
$8.6M
PE methylation in skeletal muscle energy efficiencyR01DK107397 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI FUNAI, KATSUHIKO · 2017 to 2025
$3.8M
LOOH-induced muscle atrophy with ageR01AG074535 · NIA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Micah J Drummond, Katsuhiko Funai · 2022 to 2026
$3.0M
Lands cycle and skeletal muscle insulin actionR01DK127979 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI FUNAI, KATSUHIKO · 2022 to 2025
$1.9M
Genetic Determinants of Limb Pathology in Peripheral Artery DiseaseR01HL125695 · NHLBI · EAST CAROLINA UNIVERSITY · PI MCCLUNG, JOSEPH MATTHEW · 2015 to 2019
$1.9M
Novel molecular mechanisms of skeletal muscle insulin resistance in physically inactive older adultsR01AG050781 · NIA · UNIVERSITY OF UTAH · PI DRUMMOND, MICAH J · 2016 to 2020
$1.7M
PE In Modulation of Energy Flux Through OxphosR01GM144613 · NIGMS · UNIVERSITY OF UTAH · PI FUNAI, KATSUHIKO · 2021 to 2024
$1.6M
Agilent 6550 QTOF system for U of UtahS10OD016232 · OD · UNIVERSITY OF UTAH · PI COX, JAMES ERIC · 2013 to 2013
$578k
Mitochondrial phospholipids, ROS, and disuse atrophyR21AG063077 · NIA · UNIVERSITY OF UTAH · PI FUNAI, KATSUHIKO · 2019 to 2020
$419k
Agilent 7200 GC/Q-TOF for the University of UtahS10OD021505 · OD · UNIVERSITY OF UTAH · PI COX, JAMES ERIC · 2016 to 2016
$401k
Novel molecular mechanisms of skeletal muscle insulin resistance in physically inactive older adultsR56AG050781 · NIA · UNIVERSITY OF UTAH · PI DRUMMOND, MICAH J · 2015 to 2015
$249k
NHLBI NIH HHS R01 HL125695NIA NIH HHS R01 AG050781NIA NIH HHS R01 AG074535NIA NIH HHS R21 AG063077NIA NIH HHS R56 AG050781NIDDK NIH HHS P30 DK020579NIDDK NIH HHS R01 DK107397NIDDK NIH HHS R01 DK127979NIDDK NIH HHS R03 DK109888NIDDK NIH HHS U54 DK110858NIGMS NIH HHS R01 GM144613NIH HHS S10 OD016232NIH HHS S10 OD021505
6 · The paper itself

Abstract

Obesity alters skeletal muscle lipidome and promotes myopathy, but it is unknown whether aberrant muscle lipidome contributes to the reduction in skeletal muscle contractile force-generating capacity. Comprehensive lipidomic analyses of mouse skeletal muscle revealed a very strong positive correlation between the abundance of lysophosphatidylcholine (lyso-PC), a class of lipids that is known to be downregulated with obesity, with maximal tetanic force production. The level of lyso-PC is regulated primarily by lyso-PC acyltransferase 3 (LPCAT3), which acylates lyso-PC to form phosphatidylcholine. Tamoxifen-inducible skeletal muscle-specific overexpression of LPCAT3 (LPCAT3-MKI) was sufficient to reduce muscle lyso-PC content in both standard chow diet- and high-fat diet (HFD)-fed conditions. Strikingly, the assessment of skeletal muscle force-generating capacity ex vivo revealed that muscles from LPCAT3-MKI mice were weaker regardless of diet. Defects in force production were more apparent in HFD-fed condition, where tetanic force production was 40% lower in muscles from LPCAT3-MKI compared to that of control mice. These observations were partly explained by reductions in the cross-sectional area in type IIa and IIx fibers, and signs of muscle edema in the absence of fibrosis. Future studies will pursue the mechanism by which LPCAT3 may alter protein turnover to promote myopathy.

Indexed as

1-Acylglycerophosphocholine O-AcyltransferaseAnimalsDiet, High-FatFemaleLipidomicsLysophosphatidylcholinesMaleMiceMice, Inbred C57BLMice, KnockoutMuscle ContractionMuscle, SkeletalMuscular DiseasesObesity1-Acylglycerophosphocholine O-AcyltransferaseLPCAT3 protein, mouseLysophosphatidylcholinesdiabeteslysophospholipidmyopathyskeletal muscle

Identifiers

PMID34499764
PMCPMC8439548
OpenAlexW3197407476

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.